CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial

BACKGROUND: A substantial proportion of breast cancer patients develop metastatic disease, with over 450,000 deaths globally per year. Bone is the most common first site of metastatic disease accounting for 40% of all first recurrence and 70% of patients with advanced disease develop skeletal involv...

Descripción completa

Detalles Bibliográficos
Autores principales: Coleman, Rob, Brown, Janet, Rathbone, Emma, Flanagan, Louise, Reid, Amber, Kendall, Jessica, Howell, Sacha, Twelves, Chris, Palmieri, Carlo, Anand, Anjana, MacPherson, Iain, Brown, Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6961242/
https://www.ncbi.nlm.nih.gov/pubmed/31941523
http://dx.doi.org/10.1186/s13063-019-3643-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6961242/
https://www.ncbi.nlm.nih.gov/pubmed/31941523
http://dx.doi.org/10.1186/s13063-019-3643-6

Ejemplares similares